Patient Capital Management is a Baltimore asset manager founded in 2020 by Samantha McLemore, CFA — Bill Miller's long-time co-manager (working together since 2002, running the flagship Opportunity Equity strategy since 2014). Continuing the Miller-school contrarian tradition, it practices "time arbitrage": exploiting behavioral mispricing to concentrate in controversial growth names (tech, healthcare, Bitcoin-related) at deep discounts to intrinsic value. Its site preserves Bill Miller's complete 1995-2022 market letters, alongside ongoing quarterly letters and webinars.

This report explains how Patient Capital's fund performed in Q3 2024. They shifted to small-cap and value stocks, and made contrarian bets: buying Alibaba when China was out of favor, and energy stocks (like Kosmos Energy and Seadrill) when oil prices looked weak. For everyday investors, it shows that extreme pessimism can create opportunities, but these bets are risky—for example, their new holding QXO aims for $50 billion in revenue by 2034 but hasn't closed any deals yet. It's worth reading to see how patient investors think against the crowd.
Patient Capital's Patient Opportunity Equity account delivered a net return of 5.58% in the third quarter of 2024, slightly below the S&P 500 index's 5.89%. Using a three-factor attribution model, the report indicates that allocation and stock selection effects were positive, while the interaction e
This chapter reviews the performance and portfolio adjustments of the Patient Opportunity Equity account in the third quarter of 2024. The market environment experienced a clear style rotation, with small-cap and value stocks taking over leadership from large-cap stocks. The Fed's 50bps rate cut and China's most aggressive stimulus policies since the pandemic boosted cyclical stocks.
The report argues that the shift in market leadership from large-cap to small-cap and value stocks benefits the portfolio, as the portfolio has consistently increased exposure to these two asset classes throughout the year. The author holds a contrarian view on the energy sector, believing the market is overly pessimistic about oil prices and sees long-term value in natural gas as a key transitional role in carbon neutrality.
| Metric | Portfolio | S&P 500 |
|---|---|---|
| Q3 Net Return | 5.58% | 5.89% |
| Top 10 Holdings Weight | 49.4% | 34.2% |
| Active Share | ~96% | - |
| Top Contributors | Net Contribution (bps) | Top Detractors | Net Contribution (bps) |
|---|---|---|---|
| QXO Inc. | +279 | Kosmos Energy | -80 |
| Alibaba | +129 | Precigen | -68 |
| Expedia | +82 | Seadrill | -65 |
| IAC | +67 | Alphabet | -57 |
| Illumina | +61 | Biogen | -55 |
This chapter provides an in-depth analysis of the best and worst performers in the Patient Capital portfolio during Q3. The report argues that market sentiment—particularly pessimism toward Chinese assets and cyclical concerns over energy stocks—has created significant pricing errors, offering contrarian opportunities for long-term investors.
The author’s core investment thesis is: Short-term negative market sentiment toward high-quality assets (such as the wholesale abandonment of Chinese companies or worries about energy prices) has driven their valuations well below intrinsic value, creating a "time arbitrage" opportunity for patient investors. The report highlights that the rebounds of Alibaba and Expedia demonstrate how undervalued assets can rapidly recover when the market narrative shifts. Meanwhile, the bullish stance on Kosmos Energy and Seadrill is counterintuitive, arguing that their value drivers—such as free cash flow inflection points and industry supply constraints—are independent of short-term oil price fluctuations.
| Company/Asset | Role | Key Data | Bullish/Bearish |
|---|---|---|---|
| Alibaba (BABA) | One of the top contributors | Q3 +47%; 12.4x forward P/E; repurchased 9% of shares | Bullish (valuation discount, beneficiary of China recovery) |
| Expedia (EXPE) | One of the top contributors | Repurchased 20% of shares since 2021; B2C business contributes 54% of EBITDA | Bullish (new management, tech platform, market share growth) |
| Kosmos Energy (KOS) | One of the biggest drags | 2025–2028 FCF equals current market cap | Bullish (FCF inflection point, potential acquisition target) |
| Seadrill (SDRL) | One of the biggest drags | Repurchased 17% of shares; committed to returning 50% of FCF to shareholders | Bullish (industry supply constraints, rising day rates) |
| Precigen (PGEN) | One of the biggest drags | Raised $31 million; BLA application expected by year-end | Bullish (potential first-in-class therapy, 2025 launch) |
1. Contrarian Allocation to Chinese Assets: The report suggests that when negative sentiment toward a country or sector reaches extremes (e.g., "completely abandoning Chinese companies"), it presents an opportunity to buy high-quality, undervalued assets. The Alibaba case shows that policy catalysts can quickly trigger value recovery.
2. Focus on "Time Arbitrage" Opportunities: For companies like Kosmos Energy, investors should look at the free cash flow inflection point over the next 2–3 years rather than the current high capex phase. When the market is myopic, patiently holding for cash flow release is an effective strategy.
3. Value Supply-Side Constraints: The Seadrill case demonstrates that in industries that have undergone prolonged capital depletion (e.g., massive rig scrapping), even a modest demand recovery can lead to significant pricing power and profit improvement. Such assets offer high leverage.
4. Beware of Overpricing "Hard Landing" Risks: Expedia’s rebound shows that when the market broadly fears an economic recession, sell-offs in cyclical consumer leaders (e.g., online travel) may be excessive. If economic data does not deteriorate as expected, these undervalued assets will recover.
This section is the compliance and disclosure portion at the end of the report, primarily explaining the performance calculation methodology, fee deduction standards, sources of holdings data, and the methodology for contribution analysis. This content does not involve investment analysis or market judgments but rather supplements the performance data and holdings information provided earlier with legal and technical clarifications.
None. This section does not contain any investment arguments or market judgments; it is solely intended to clarify the technical details and legal boundaries of the performance presentation.
None. This section does not mention any specific companies or assets.
None. This section does not provide any investment advice or directional judgments. Investors should focus solely on the performance and holdings analysis sections earlier in the report; this section is only intended to ensure data transparency and compliance.